Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Siena

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisC Cremolini, M Di Bartolomeo, A Amatu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2006
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in EuropeL Barkholt, M Bregni, M Remberger, et al.
Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia|August 6, 2010
[Algorithm for assessment of exposure to asbestos]V Martines, M Fioravanti, A Anselmi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC studyA Sartore-Bianchi, F Toscano, D P Bernasconi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)S Cascinu, F Graziano, F Ferraù, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2016
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancerA Amatu, L Barault, C Moutinho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerJ Y Douillard, S Siena, J Cassidy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2015
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancerL Barault, A Amatu, F E Bleeker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II studyA Necchi, L Mariani, M Di Nicola, et al.
ESMO Open|July 16, 2025
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world datasetV Daprà, A Gandini, F Schietroma, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisC Cremolini, M Di Bartolomeo, A Amatu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2006
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in EuropeL Barkholt, M Bregni, M Remberger, et al.
Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia|August 6, 2010
[Algorithm for assessment of exposure to asbestos]V Martines, M Fioravanti, A Anselmi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC studyA Sartore-Bianchi, F Toscano, D P Bernasconi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)S Cascinu, F Graziano, F Ferraù, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2016
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancerA Amatu, L Barault, C Moutinho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerJ Y Douillard, S Siena, J Cassidy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2015
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancerL Barault, A Amatu, F E Bleeker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II studyA Necchi, L Mariani, M Di Nicola, et al.
ESMO Open|July 16, 2025
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world datasetV Daprà, A Gandini, F Schietroma, et al.
Pageof 17